Synergy's IBS drug delivers positive top-line results in mid-stage trial

|About: Synergy Pharmaceutical... (SGYP)|By:, SA News Editor

Synergy Pharmaceuticals' (SGYP) plecanatide shows a statistically significant improvement in complete spontaneous bowel movement (CSBM) frequency in patients with irritable bowel syndrome with constipation (IBS-C) in a Phase 2b clinical trial.

Patients also experienced a statistically significant improvement in change from baseline versus placebo in worst abdominal pain and met the FDA overall responder endpoint for IBS-C over the 12-week treatment period.

The company plans to start a Phase 3 trial in the second half.

Shares are up 5% premarket on robust volume.